Literature DB >> 6692314

Breast-conserving treatment for breast cancer in Stockholm, Sweden, 1977 to 1981.

B Cedermark, J Askergren, A Alveryd, U Glas, L Karnström, A Somell, N O Theve, A Wallgren.   

Abstract

Since 1977 patients living in Stockholm with Stage I breast cancer fulfilling specific criteria are offered breast-conserving treatment. The treatment includes a partial mastectomy and a low-axillary dissection followed by radiotherapy, 5000 rad, to the remaining breast. Between 1977 and 1981, 262 patients underwent the breast conserving therapy. One hundred eighty-six patients had pathologic Stage I tumors. Radiotherapy was given to 158 of those patients. During the follow-up time (6 months to 5 years), 4 of 186 patients had recurrence to the breast. Two of those had not received radiotherapy. Recurrent tumor in regional lymph nodes occurred in 4/186, and distant metastases in 10/186 patients. Six patients have died of their disease. The cosmetic results were favorable overall, but often impaired when surgical complications occurred. A comparison between these results and those obtained in similar patients treated with modified radical mastectomy with a low-axillar dissection followed by radiotherapy to the remaining breast seems to be an alternative treatment to modified radical mastectomy. Longer follow-up time is needed before final conclusions can be drawn.

Entities:  

Mesh:

Year:  1984        PMID: 6692314     DOI: 10.1002/1097-0142(19840315)53:6<1253::aid-cncr2820530606>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Cancer cell emboli in the pectoral lymphatics of patients with breast cancer.

Authors:  K Nakao; M Miyata; T Aono; N Ogino; T Tsumori; Y Kawashima
Journal:  Jpn J Surg       Date:  1989-07

Review 2.  Review of general surgery 1984-85.

Authors:  H Ellis
Journal:  Postgrad Med J       Date:  1985-11       Impact factor: 2.401

3.  Treatment of primary breast cancer without mastectomy. The Los Angeles community experience and review of the literature.

Authors: 
Journal:  Ann Surg       Date:  1986-08       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.